Don't forget the two EMA Rapporteurs were assigned soon after Anavex was told to file for full approval. I bet those two have already done a fair amount of research months before Anavex File was received and accepted. I don't know from my reading of the EMA rules that a Rapporteur could not ask questions prior to arrival at this Clock Stop One? Also don't forget how we were listed in the formal notice of acceptance Alzheimers and Dementia. John k9uwa
At a minimum, there should/will be questions/concerns about titration and statistical methods used to calculate the drug’s efficacy.
I have to agree with Mikedotcom that this has been a POS stock for the nearly 10 years I’ve owned it. I am very tired of “just wait 2 more years” that I’ve been reading for the past 9 years. I do finally think the next 2 years will be make or break here. We either go parabolic or wind up like SAVA.